Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study – BREAST

Cortés, A; López-Miranda, E; Fernández-Ortega, A; Carañana, V; Servitja, S; Urruticoechea, A; Lema-Roso, L; Márquez, A; Lazaris, A; Alcalá-López, D; Mina, L; Gener, P; Rodríguez-Morató, J; Antonarellij, G; Llombart-Cussac, A; Pérez-García, J; Cortés, J – 2024 – 10.1016/j.breast.2024.103834